Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study

NCT07709624 · clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

TTY Biopharm